Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOVXNASDAQ:MBRXNASDAQ:NEUPNASDAQ:NOVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOVXGeoVax Labs$0.96+0.4%$1.00$0.73▼$11.18$15.35M3.45689,142 shs200,677 shsMBRXMoleculin Biotech$0.30-3.6%$0.82$0.25▼$4.71$4.27M1.561.89 million shs1.38 million shsNEUPNeuphoria Therapeutics$7.04+0.6%$5.99$2.12▼$12.55$13.24M0.46291,615 shs13,180 shsNOVNNovan$0.00$0.08▼$3.33$2.64M-0.06602,421 shs7.19 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOVXGeoVax Labs0.00%+1.69%-8.21%-9.43%-69.86%MBRXMoleculin Biotech0.00%+16.93%-65.18%-67.81%-91.13%NEUPNeuphoria Therapeutics0.00%+2.94%+6.87%+21.53%+699,999,900.00%NOVNNovan0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGOVXGeoVax Labs3.5083 of 5 stars3.65.00.00.02.91.70.6MBRXMoleculin Biotech3.2776 of 5 stars3.52.00.00.04.01.71.3NEUPNeuphoria Therapeutics1.8713 of 5 stars3.50.00.00.02.60.00.6NOVNNovanN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOVXGeoVax Labs 3.29Buy$11.101,052.05% UpsideMBRXMoleculin Biotech 3.00Buy$4.001,228.90% UpsideNEUPNeuphoria Therapeutics 3.00Buy$21.00198.30% UpsideNOVNNovan 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NOVN, MBRX, NEUP, and GOVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.005/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.004/16/2025GOVXGeoVax LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025GOVXGeoVax LabsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $8.504/10/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOVXGeoVax Labs$3.95M3.89N/AN/A$0.48 per share2.01MBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/ANEUPNeuphoria Therapeutics$10K1,323.52N/AN/A$15.85 per share0.44NOVNNovan$24.71M0.00N/AN/A$0.19 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)NEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/AN/ANOVNNovan-$31.31M-$1.32N/AN/AN/A-128.61%-700.28%-39.58%N/ALatest NOVN, MBRX, NEUP, and GOVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q3 2025NEUPNeuphoria Therapeutics-$0.47$6.55+$7.02$6.55N/A$15.00 million5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOVXGeoVax LabsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ANOVNNovanN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOVXGeoVax LabsN/A3.623.62MBRXMoleculin BiotechN/A1.351.35NEUPNeuphoria TherapeuticsN/A11.0111.01NOVNNovanN/A0.740.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOVXGeoVax Labs6.09%MBRXMoleculin Biotech15.52%NEUPNeuphoria Therapeutics15.90%NOVNNovan14.51%Insider OwnershipCompanyInsider OwnershipGOVXGeoVax Labs5.70%MBRXMoleculin Biotech1.90%NEUPNeuphoria Therapeutics0.69%NOVNNovan1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOVXGeoVax Labs1015.93 million15.02 millionNot OptionableMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ANOVNNovan9028.02 million27.65 millionNot OptionableNOVN, MBRX, NEUP, and GOVX HeadlinesRecent News About These CompaniesHow Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug marketSeptember 18, 2024 | invezz.comINovartis AGFebruary 27, 2024 | wsj.comNovartis AG Registered SharesFebruary 16, 2024 | morningstar.comMNovartis AG Registered Shares NOVNOctober 31, 2023 | morningstar.comMNovan: Regulation Fd Disclosure, Financial Statements And ExhibitsOctober 25, 2023 | cbonds.comCNovan reaches deals to sell assets in bankruptcy caseSeptember 8, 2023 | bizjournals.comFirm Retention Summary: NovanAugust 8, 2023 | msn.comNovan (NOVN) Price Target Increased by 43.52% to 15.81August 3, 2023 | msn.comNovan files patent for a composition and method of treating skinAugust 1, 2023 | pharmaceutical-technology.comPInsider Sale Alert: Novan Inc. [NOVN] – Is it Time to sell?July 25, 2023 | knoxdaily.comKNOVN short interest surges, indicating growing pessimism among investorsJuly 21, 2023 | knoxdaily.comKNOVN stock rated an Overweight by Cantor FitzgeraldJuly 18, 2023 | knoxdaily.comKNovan Shares Hit 52-Week Low After Bankruptcy DeclarationJuly 17, 2023 | marketwatch.comDurham biotech Novan to sell assets, files for bankruptcyJuly 17, 2023 | wraltechwire.comWPotential Price Increase for Novan Inc. (NOVN) After Recent Insider ActivityJuly 11, 2023 | knoxdaily.comKNovan Inc. [NOVN] Investment Guide: What You Need to KnowJuly 3, 2023 | knoxdaily.comKCIMB appoints Novan Amirudin as CIMB Investment Bank CEOJune 16, 2023 | malaymail.comMCIMB appoints Novan Amirudin as CEO of CIMB Investment BankJune 16, 2023 | thestar.com.myTNovan Amirudin new CIMB Investment Bank CEOJune 16, 2023 | freemalaysiatoday.comFDurham pharma Novan slashes 50% of workforce, mulls sale of assetsJune 1, 2023 | wraltechwire.comWNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNOVN, MBRX, NEUP, and GOVX Company DescriptionsGeoVax Labs NASDAQ:GOVX$0.96 +0.00 (+0.36%) As of 10:43 AM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Moleculin Biotech NASDAQ:MBRX$0.30 -0.01 (-3.59%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Neuphoria Therapeutics NASDAQ:NEUP$7.04 +0.04 (+0.57%) As of 10:41 AM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Novan NASDAQ:NOVNNovan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
